OncoMatch/Clinical Trials/NCT06562348
The ctDNA-RECIST Trial Part One
Is NCT06562348 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for gastrointestinal neoplasm.
A study investigating if analysis of circulating tumor DNA (ctDNA) can guide palliative treatment in patients with gastrointestinal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
adequate bone marrow function allowing systemic chemotherapy
Kidney function
adequate renal function allowing systemic chemotherapy
Liver function
adequate liver function allowing systemic chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify